# DESTINY-BTC01 (NCT06467357)

> Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06467357
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: AstraZeneca
- Conditions: Biliary Tract Cancer
- Interventions: Gemcitabine; Cisplatin; Durvalumab; Trastuzumab deruxtecan; Rilvegostomig
- Enrollment: 620
- Primary outcome: Safety Run In: To evaluate the safety and tolerability of T-DXd with rilvegostomig
- Primary outcome: Randomized Portion: To evaluate the efficacy of T-DXd with rilvegostomig vs Standard of Care (SoC) in terms of Overall Survival in the FAS (HER2 IHC 3+) population

## Commentary we found

- YouTube: 7
- Podcasts: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=destiny-btc01-nct06467357

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06467357", "email": "<work email>"}; the inbox owner confirms by the emailed link.